MAGIC Ruxolitinib for aGVHD

Clinical trial NCT06936566 · RECRUITING

Trial details

NCT number: NCT06936566
Sponsor: John Levine
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Acute Graft-versus-host Disease Allogeneic Bone Marrow Transplantation Adverse Effects

Start date: 2025-05-14
Primary completion: 2027-06-01
Enrollment: 98

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.